Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (91-100 of 336) with videos related to

Pageof 34
Sort By:
Therapeutic Advances in Urology|July 22, 2021
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, et al.
Oncology Research|January 8, 2026
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic ReviewGiacomo Iovane, Luca Traman, Michele Maffezzoli, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enoughMelissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, et al.
Critical Reviews in Oncology/Hematology|February 5, 2021
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysisMelissa Bersanelli, Sebastiano Buti, Patrizia Giannatempo, et al.
Tumori|September 23, 2015
Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunderMelissa Bersanelli, Paola Bini, Enrico Rabaiotti, et al.
Minerva Urology and Nephrology|May 11, 2023
Prognostic models for patients with metastatic urothelial carcinoma: why use them?Michele Maffezzoli, Davide Campobasso, Sara E Rebuzzi, et al.
Immunotherapy|November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysisMatteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Therapeutic Advances in Urology|November 4, 2021
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysisCarlo Cattrini, Carlo Messina, Chiara Airoldi, et al.
Anti-Cancer Drugs|April 5, 2013
Chemotherapy in metastatic renal cell carcinoma today? A systematic reviewSebastiano Buti, Melissa Bersanelli, Angelica Sikokis, et al.
World Journal of Radiology|October 11, 2021
Review on radiological evolution of COVID-19 pneumonia using computed tomographyChiara Casartelli, Fabiana Perrone, Maurizio Balbi, et al.
Pageof 34

Showing results (91-100 of 336) with videos related to

Sort By:
Pageof 34
Therapeutic Advances in Urology|July 22, 2021
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, et al.
Oncology Research|January 8, 2026
Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic ReviewGiacomo Iovane, Luca Traman, Michele Maffezzoli, et al.
Critical Reviews in Oncology/Hematology|May 22, 2019
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enoughMelissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, et al.
Critical Reviews in Oncology/Hematology|February 5, 2021
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysisMelissa Bersanelli, Sebastiano Buti, Patrizia Giannatempo, et al.
Tumori|September 23, 2015
Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunderMelissa Bersanelli, Paola Bini, Enrico Rabaiotti, et al.
Minerva Urology and Nephrology|May 11, 2023
Prognostic models for patients with metastatic urothelial carcinoma: why use them?Michele Maffezzoli, Davide Campobasso, Sara E Rebuzzi, et al.
Immunotherapy|November 27, 2018
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysisMatteo Santoni, Alessandro Conti, Sebastiano Buti, et al.
Therapeutic Advances in Urology|November 4, 2021
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysisCarlo Cattrini, Carlo Messina, Chiara Airoldi, et al.
Anti-Cancer Drugs|April 5, 2013
Chemotherapy in metastatic renal cell carcinoma today? A systematic reviewSebastiano Buti, Melissa Bersanelli, Angelica Sikokis, et al.
World Journal of Radiology|October 11, 2021
Review on radiological evolution of COVID-19 pneumonia using computed tomographyChiara Casartelli, Fabiana Perrone, Maurizio Balbi, et al.
Pageof 34